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Our thanks to Durukan and col-
leagues for their positive comments
about our meta-analysis on bleeding
after cardiopulmonary bypass (CPB).1
Weagree that it is important to consider
the role of albumin in preserving
coagulation system function among
patients undergoingCPB. In particular,
CPB places these patients at risk for
acquired transient platelet dysfunction
attended by diffuse nonsurgical post-
operative bleeding.
A protective effect against hemor-
rhage is suggested by observations in
cardiac surgical patients with albumin
deficiency. In a prospective study of
5168 consecutive patients undergoing
coronary artery bypass grafting, preop-
erative hypoalbuminemia (serumalbu-
min<25 g $ L1) was an independent
risk factor of reexploration for bleed-
ing, with an odds ratio (OR) of 1.4
(95% confidence interval [CI],
1.0-2.1; P ¼ .04) after adjustment for
17 other variables.2 Preoperative hypo-
albuminemia was also an independent
risk factor for mortality in that study
(OR, 2.0; 95% CI, 1.3-3.0; P ¼ .002).
In a meta-analysis of 21 controlled
clinical trials with 1346 total patients,
extracorporeal circuit priming with al-
bumin maintained on-bypass platelet310 The Journal of Thoracic and Ccounts at a significantly higher level
than that seen with crystalloid alone.3
Furthermore, albumin priming was
significantly associated with postop-
erative reductions in thrombocytope-
nia, blood loss, and reoperations for
bleeding relative to crystalloid-alone
priming in a retrospective study of
377 patients undergoingCPB. In a ran-
domized trial, addition of albumin to
a priming solution containing artificial
colloid (dextran 70) also resulted in
significantly higher platelet counts as
long as 48 h after CPB, with signifi-
cantly less blood loss from the medi-
astinal drains.
Albumin is capable of modulating
platelet activity through biologically
specific mechanisms. Platelet aggreg-
ability can be modulated both by com-
plexes of fatty acids bound to albumin
and by nitric oxide–albumin adduct.
Albumin also binds with high affinity
to platelet-activating factor, thereby
reducing its activity, and this binding
occurs exclusively in domain II of
the albumin molecule extending
from polypeptide chain amino acid
position 240 to 386.
As Lange and coauthors4 acknowl-
edge, it is accepted that albumin
does not interfere with coagulation,
other than possibly by hemodilution.
Those authors nevertheless cite two
pieces of contrary evidence, neither
concerned with cardiac surgery. First,
after in vitro dilution of blood samples
from patients scheduled for elective
general surgery, albumin impaired
thromboelastographically assessed
coagulation to a greater extent than
normal saline solution or hydrox-
yethyl starch 450/0.7. However, in 3
randomized trials of colloid use
in vivo among patients undergoing
CPB, 1 involving pump priming and
the other 2 involving postoperative
volume expansion, albumin signifi-
cantly improved clotting as measured
by thromboelastography compared
with hydroxyethyl starch 120/0.7,
130/0.4, 200/0.5, or 450/0.7.1
Second, in a subgroup analysis of
data from the SAFE (Saline versusardiovascular Surgery c January 2013Albumin Fluid Evaluation) study, ac-
tivated partial thromboplastin time
on day 2 increased by 7% in patients
receiving albumin while decreasing
2% in recipients of normal saline so-
lution.5 The SAFE study investigators
conceded that this difference was
‘‘small and thus of questionable clini-
cal importance.’’5 Furthermore, the
difference can be readily explained
by greater hemodilution in the albu-
min group. Thus the ratio of saline so-
lution to albumin infused during the
first 2 days of the SAFE study was
only 1.4, whereas in a randomized
trial of patients undergoing CPB, the
ratio needed for equivalent plasma
volume expansion was 5.8.
From a physiologic perspective, it
appears highly unlikely that albumin,
the most abundant protein in plasma,
would specifically interfere with co-
agulation. The components of the co-
agulation system have evolved to
function under constant exposure to
serum albumin concentrations of ap-
proximately 35 to 50 g $ L1 during
normal conditions.
Albumin remains the criterion stan-
dard for fluid management in cardiac
surgery. A chief advantage, either for
extracorporeal circuit priming or peri-
operative volume expansion, is main-
tenance of a competent coagulation
system.
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http://dx.doi.org/10.1016/
j.jtcvs.2012.09.048TABLE 1. Characteristics of patients treated with bivalirudin after cardiac surgery
Before
(2004-2006)
After
(2007-2010)
Thrombocytopenia 15.1%
463/3065
14.5%
476/3288
DTI use in patients with thrombocytopenia 17.5%
81/463
23.1%
110/476
HITTS (per decreased platelets) 4.3%
20/463
5.5%
26/476
HITTS (per total adult patients) 0.7%
20/3065
0.8%
26/3288
HITTS mortality 60.0%
12/20
23.0%
6/26
Thrombocytopenia is defined as a 50% decrease in platelets from preoperative baseline by 24 hours after cardiopul-
monary bypass. Mortality is defined as death within index admssion. DTI, Direct thrombin inhibitor; HITTS,
heparin-induced thrombocytopenia and thrombosis syndrome.AORTIC ARCH INTERRUPTION
WITHOUT DUCTUS
ARTERIOSUS AND NO
VENTRICULAR SEPTAL
DEFECT
To the Editor:
We read the interesting case report
by Cazavet and associates1 on ‘‘an in-
fant with a previously unrecorded type
of aortic arch interruption.’’ However,
similar types of aortic arch interrup-
tion without ductus arteriosus and
without ventricular septal defect, al-
though rare, have been previously de-
scribed since 1964.2-6 The common
features of these unusual patients
were the longevity up to adolescence
with no severe symptoms and
the presence of extensive collateral
circulation supplying the descending
aorta.2-6 Surgical treatment was also
reported in relation to the various
anatomic patterns.2-6 In the field of
pediatric cardiology, sometimes some
old scientific papers can represent
important sources of knowledge.
The interesting new aspect de-
scribed by Cazavet and associates1 is
the association with del 22q11 and
the relative embryogenetic implica-
tions that expand the spectrum
of cardiovascular defects of this
syndrome.
Carolina Putotto, MD
Marta Unolt, MD
Dario Marino, MD
Department of Pediatrics
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MANAGEMENT OF
HEPARIN-INDUCED
THROMBOCYTOPENIA IN
PATIENTS AFTER CARDIAC
SURGERY
To the Editor:
In a recent publication, Demma,
Paciullo, and Levy1 evaluated the rec-
ognition and treatment of heparin-
induced thrombocytopenia (HIT) in
patients after cardiothoracic surgery
using the direct thrombin inhibitor
(DTI) argatroban. We agree that the
detection and management of HIT in
patients who have had cardiac surgery
is of clinical importance, and we haveof Thoracic and Cardiovascular Surgeused a similar method of HIT identifi-
cation and treatment with the DTI
bivalirudin.
Our familiarity with the use of biva-
lirudin was heightened after our par-
ticipation in the CHOOSE-ON trial
published in 2007, which evaluated
the use of this DTI during cardiopul-
monary bypass in patients having car-
diac surgery.2 Since then, we have
standardized our method of identify-
ing HIT patients postoperatively and
treating them with bivalirudin. To de-
tect HIT, we use a method similar to
that of Demma, Paciullo, and Levy1
in which patients who score in the
moderate range on the 4-Ts schema3
are subjected to a platelet factor 4/
heparin immunoassay. Occasionally,
we will also confirm the diagnosis
with a serotonin release assay. To
then distinguish HIT from hemodilu-
tion or other causes of thrombocyto-
penia, we also categorize the patterns
of platelet counts as outlined by Pou-
plard and colleagues.4
Our standardization of detection
methods did not alter the number of
patients who received a diagnosis of
HIT (14.5% compared with 15.1%
before 2007). However, we did see
an increased rate in the use of
bivalirudin to treat thrombocytopenia
(23.1% compared with 17.5%)
(Table 1). This suggests that our stan-
dardization procedures may have re-
sulted in earlier identification and
medical management of HIT.ry c Volume 145, Number 1 311
